Skip to content

Elanco Animal Health Inc (ELAN) stock: revenue, earnings & dividend

Elanco Animal Health Inc (ELAN, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener ELAN · NYSE Pharma & Biotech US-IN

Key figures

Fiscal year
2025
Revenue
4.72 bn $
Revenue growth
6.2 %
Revenue growth 5y (p.a.)
7.6 %
Net income
-232 m $
Net margin
-4.9 %
Operating margin
–
Earnings per share (diluted)
-0.47 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
13.4 bn $
Equity
6.55 bn $
Equity ratio
49 %
Return on equity
-3.5 %
Cash
545 m $
Operating cash flow
560 m $
Free cash flow
284 m $
Shares outstanding
499,827,067

History

Revenue by fiscal year

2016 2.91 bn $
2017 2.89 bn $
2018 3.07 bn $
2019 3.07 bn $
2020 3.27 bn $
2021 4.76 bn $
2022 4.41 bn $
2023 4.42 bn $
2024 4.44 bn $
2025 4.72 bn $

Net income by fiscal year

2016 -47.9 m $
2017 -310.7 m $
2018 86.5 m $
2019 68 m $
2020 -574 m $
2021 -483 m $
2022 -78 m $
2023 -1.23 bn $
2024 338 m $
2025 -232 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20254.72 bn $-232 m $-0.47 $–560 m $
20244.44 bn $338 m $0.68 $–541 m $
20234.42 bn $-1.23 bn $-2.50 $–271 m $
20224.41 bn $-78 m $-0.16 $–452 m $
20214.76 bn $-483 m $-0.99 $–483 m $
20203.27 bn $-574 m $-1.30 $–-41 m $
20193.07 bn $68 m $0.18 $–224 m $
20183.07 bn $86.5 m $0.28 $–487 m $
20172.89 bn $-310.7 m $-1.06 $–174 m $
20162.91 bn $-47.9 m $––156 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)